Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Biome Australia Ltd ( (AU:BIO) ) has provided an update.
Biome Australia Limited reported a breakthrough financial year in 2025, achieving its first net profit of $214,656 and a 41.6% increase in sales revenue to $18.4 million. The company saw substantial growth across all key metrics, with international sales rising by 69% and strategic partnerships established in Canada, Ireland, the UK, and New Zealand. Biome’s Activated Probiotics brand became the second-largest in probiotic revenue within community pharmacies, and the company is on track to meet its Vision 27 forecast of $75 million in cumulative sales for FY25-27.
The most recent analyst rating on (AU:BIO) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Biome Australia Ltd stock, see the AU:BIO Stock Forecast page.
More about Biome Australia Ltd
Biome Australia Limited is a microbiome health company that focuses on developing and marketing probiotic products. The company is known for its Activated Probiotics brand, which has secured a strong position in the community pharmacy sector. Biome’s market focus includes domestic and international expansion, with a significant emphasis on customer service, innovative health-targeted products, and clinical backing.
Average Trading Volume: 392,916
Technical Sentiment Signal: Strong Buy
See more data about BIO stock on TipRanks’ Stock Analysis page.